Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318952 | 0.88 | SIGMAR1 (0.58) | SIGMAR1MGLLOPRM1KCNH2CHRM2 | |
| Hydrochloric Acid SCHEMBL18695858 | 0.87 | SIGMAR1 (0.57) | SIGMAR1MGLLOPRM1KCNH2CHRM2 | |
| SCHEMBL17319033 | 0.82 | SIGMAR1 (0.62) | SIGMAR1OPRM1KCNH2CHRM2DRD2 | |
| SCHEMBL17318852 | 0.81 | CHRM2 (0.60) | SIGMAR1OPRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL18785075 | 0.81 | SLC6A3 (0.56) | SIGMAR1MGLLOPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL18695950 | 0.81 | SIGMAR1 (0.61) | SIGMAR1OPRM1KCNH2CHRM2DRD2 | |
| SCHEMBL18695823 | 0.81 | SIGMAR1 (0.62) | SIGMAR1MGLLOPRM1KCNH2OPRK1 | |
| SCHEMBL20272180 | 0.79 | SIGMAR1 (0.76) | SIGMAR1 | |
| SCHEMBL26552039 | 0.79 | MGLL (0.60) | SIGMAR1MGLLOPRM1CHRM2CHRM3 | |
| SCHEMBL17319093 | 0.79 | MGLL (0.52) | SIGMAR1MGLLOPRM1KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339597-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-10-29 | — | — | US | claimed |
| US-20170101420-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-04-13 | — | — | US | claimed |
| EP-3149007-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | claimed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | claimed |
| US-20200339597-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-10-29 | — | — | US | disclosed |
| US-20200339597-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-10-29 | — | — | US | disclosed |
| US-10703765-B2 | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-07-07 | — | — | US | disclosed |
| US-10703765-B2 | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-07-07 | — | — | US | disclosed |
| US-20170101420-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-04-13 | — | — | US | disclosed |
| US-20170101420-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-04-13 | — | — | US | disclosed |
| US-20170101420-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-04-13 | — | — | US | disclosed |
| EP-3149007-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703765-B2 | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | SIGMAR1 2/4885MGLL 906/4885OPRM1 3/4885 |
| US-20170101420-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | SIGMAR1 2/4885MGLL 906/4885OPRM1 3/4885 |
| US-20200339597-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | SIGMAR1 2/4885MGLL 906/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.